# Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China

> **NCT00408993** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 215 (actual)

## Conditions studied

- Diabetic Neuropathies

## Interventions

- **DRUG:** Duloxetine Hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00408993
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2011-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00408993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00408993, "Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00408993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*